BNB Plus (BNBX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting will be held virtually on May 22, 2025, with shareholders able to vote and ask questions online.
Shareholders will vote on electing six directors, ratifying the new auditor, approving a reverse stock split, warrant exercisability, amending the equity plan, and executive compensation matters.
The Board recommends voting in favor of all proposals, emphasizing the importance of shareholder participation.
Voting matters and shareholder proposals
Proposals include electing six directors, ratifying CBIZ CPAs P.C. as auditor, authorizing a reverse stock split (1-for-5 to 1-for-50), approving warrant exercisability, amending the 2020 Equity Incentive Plan, and advisory votes on executive compensation and its frequency.
The Board recommends a three-year frequency for say-on-pay votes.
Shareholders of record as of April 3, 2025, are eligible to vote.
Board of directors and corporate governance
Six directors are nominated for re-election, all current members, with a majority deemed independent under Nasdaq rules.
The Board has audit, compensation, and nominating committees, all composed entirely of independent directors.
The Board’s leadership structure combines the roles of CEO and Chairman, with risk oversight distributed among committees.
Latest events from BNB Plus
- Stockholders will vote on a reverse stock split to maintain Nasdaq listing and support strategic options.BNBX
Proxy Filing12 Mar 2026 - Net loss surged on lower revenue and one-time digital asset strategy expenses.BNBX
Q1 202612 Feb 2026 - BNBX targets 9%-12% annualized yield on BNB, offering direct exposure to Binance’s ecosystem.BNBX
Fintech & DATS Investor Conference4 Feb 2026 - BNB Plus targets 8%-12% annualized yield via BNB strategies and transparent treasury management.BNBX
Digital Asset Treasury Virtual Investor Conference3 Feb 2026 - Revenue fell sharply, but net income turned positive on a warrant gain; growth expected in FY25.BNBX
Q3 20242 Feb 2026 - GMP-ready linear DNA and RNA platforms enable rapid, high-quality genetic medicine production.BNBX
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026 - Shifted to a BNB treasury model, raised $26.8M, cut costs 70%, and posted a $15.2M net loss.BNBX
Q4 202529 Dec 2025 - Revenue up 34%, exited DNA Tagging, GMP DNA site launched, but net loss widened on warrant charges.BNBX
Q1 202524 Dec 2025 - Raising capital to fund a BNB-focused treasury strategy amid high crypto and regulatory risks.BNBX
Registration Filing22 Dec 2025